Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25412507 | 0.86 | LMNA (0.43) | LMNAPOLBSMN1; SMN2ATMGBA2 | |
| SCHEMBL30002152 | 0.86 | SMN1; SMN2 (0.50) | LMNAPOLBSMN1; SMN2ATMALDH1A1 | |
| SCHEMBL23859720 | 0.84 | LMNA (0.49) | LMNAPOLBSMN1; SMN2ATMGBA2 | |
| SCHEMBL30013395 | 0.82 | LMNA (0.48) | LMNAPOLBSMN1; SMN2ATMGBA2 | |
| SCHEMBL30467459 | 0.81 | LMNA (0.47) | LMNAPOLBSMN1; SMN2ATMGBA2 | |
| SCHEMBL8821262 | 0.80 | LMNA (0.51) | LMNAPOLBSMN1; SMN2ATMGBA2 | |
| SCHEMBL31338431 | 0.80 | SMN1; SMN2 (0.44) | LMNAPOLBSMN1; SMN2ATMGBA2 | |
| SCHEMBL30376526 | 0.80 | LMNA (0.43) | LMNAPOLBSMN1; SMN2GBA2ALDH1A1 | |
| SCHEMBL31282074 | 0.79 | LMNA (0.44) | LMNAPOLBSMN1; SMN2ATMGBA2 | |
| SCHEMBL30177247 | 0.79 | LMNA (0.44) | LMNAPOLBSMN1; SMN2ATMGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024263586-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | PAQ Therapeutics Inc. (US) | 2024-12-26 | — | — | WO | disclosed |
| EP-4419207-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023067354-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| US-10017500-B2 | 1,3-benzodioxole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20170073335-A1 | 1,3-BENZODIOXOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073335-A1 | 1,3-BENZODIOXOLE DERIVATIVE | EZH1, EZH2, BMI1 | LMNA 4047/4885POLB 3940/4885SMN1; SMN2 1920/4885 |
| US-10017500-B2 | 1,3-benzodioxole derivative | EZH1, EZH2, BMI1 | LMNA 4047/4885POLB 3940/4885SMN1; SMN2 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.